EUVIMEDScopri EUVIMED
EUVIMED · CrossrefJournal

Liver Cancer

ISSN 2235-1795 · S. Karger AG

Latest articles

  1. Survival Benefit of Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

    Hidekatsu Kuroda, Takuya Sho, Goki Suda, Masashi Ninomiya, Tamami Abe, Kei Endo, Takuya Watanabe, Yudai Fujiwara, Tokio Sasaki, Yuichi Yoshida, Keisuke Kakisaka, Takayoshi Oikawa, Kei Sawara, Mio Tsuruoka, Hiroshi Numao, Go Igarashi, Chikara Iino, Kenta Yoshida, Satoshi Sato, Tomohiro Katsumi, Keita Maki, Wataru Sato, Shinichiro Minami, Kazumichi Abe, Masashi Fujita, Nobukazu Tanabe, Yoshiya Yamamoto, Masaru Baba, Takashi Meguro, Naoya Sakamoto, Yoshiyuki Ueno, Takayuki Matsumoto

    Published: 2026-11-17DOI: 10.1159/lic/admag030

  2. Alcohol Plays a Detrimental Role in the Prognosis of Hepatocellular Carcinoma Related to Steatotic Liver Disease

    Stefano Gitto, Alessandro Vitale, Gianluca Svegliati-Baroni, Giulio Marchesini, Francesco Paolo Russo, Luca Miele, Claudia Campani, Valentina Adotti, Martina Rosi, Francesco Vizzutti, Mariarosaria Marseglia, Andrea Martini, Angelo Sangiovanni, Giuseppe Cabibbo, Giacomo Zaccherini, Giorgia Ghittoni, Maria Di Marco, Francesco Giuseppe Foschi, Filomena Morisco, Sara Grasselli, Carlo Saitta, Francesca Romana Ponziani, Maurizia Rossana Brunetto, Donatella Magalotti, Francesco Azzaroli, Andrea Mega, Rodolfo Sacco, Gerardo Nardone, David Sacerdoti, Sara Boninsegna, Gianpaolo Vidili, Franco Trevisani, Edoardo G. Giannini, Fabio Marra

    Published: 2026-07-02DOI: 10.1159/000553063

  3. Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study

    Masayuki Ueno, Yung-Yeh Su, Atsushi Takai, Yi-Hsiang Huang, Hiroki Morimura, Norihiro Nishijima, Shi-Ming Lin, Ching‑Wei Chang, Satoru Iwamoto, Shu Nagatomo, Hsueh-Chou Lai, Takeshi Mitani, Atsuyuki Ikeda, Yoshito Uenoyama, Makoto Umeda, San-Chi Chen, Chien-Huai Chuang, Shiue-Wei Lai, Teng-Yu Lee, Shigeharu Nakano, Chia-Yen Dai, Tomoyuki Goto, Tung-Hung Su, Ching Sheng Hsu, Ching-Chu Lo, Haruhiko Takeda, Yukio Osaki, Etsuro Hatano, Pei-Chang Lee, Po-Ting Lin, Hung-Wei Wang, Wei-Fan Hsu, Tsung-Hao Liu, Hiroshi Seno

    Published: 2026-06-01DOI: 10.1159/000552808

  4. The 2024 International Liver Transplant Society and International Liver Cancer Association Consensus Recommendations for Liver Transplantation for Liver Cancer

    Sudha Kodali, Laura Kulik, Antonio D'Alessio, Eleonora De Martin, Abdul Rahman Hakeem, Monika Lewinska, Stacie Lindsey, Ken Liu, Zorana Maravic, Madhukar S. Patel, David J. Pinato, Ashwin Rammohan, Nicole Rich, Marco Sanduzzi Zamparelli, David W. Victor, Carmen Vinaxia, Elizabeth W. Brombosz, Augusto Villanueva, Tim Meyer, Nazia Selzner, R. Mark Ghobrial, Mohamed Rela, Gonzalo Sapisochin

    Published: 2026-04-25DOI: 10.1159/000550600

  5. Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma

    Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Takanori Matsuura, Yoshihide Ueda, Soo Ki Kim, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa

    Published: 2026-04-02DOI: 10.1159/000550924

Volumes

2026 · 852025 · 842024 · 892023 · 652022 · 682021 · 682020 · 822019 · 642018 · 472017 · 552016 · 332015 · 312014 · 242013 · 252012 · 26

Conoscenze adatte al tuo lavoro.

Dall’inizio gratuito alla ricerca bibliografica personale, fino alla Research Suite completa.

Visualizza tariffe →

Sono inclusi tutti i testi integrali degli editori?

No. Citazioni, abstract e testi integrali sono contenuti diversi. La disponibilità dipende dalla fonte, dall’accesso aperto e dalle licenze esistenti. Un piano EUVIMED non sostituisce diritti aggiuntivi degli editori.